Recent Data Surrounding the Appropriate Candidates for Long-Acting Cabotegravir for HIV Prevention

In this video, Dr. Sherman explains the recent data surrounding the right candidates for long-acting cabotegravir for HIV prevention.

Pharmacy Times spoke with Dr. Elizabeth Sherman, PharmD, about her session at the ASHP Midyear 2021 conference, titled "Long Acting Antiretroviral Therapy for the Treatment and Prevention of HIV Infection”.

In this video, Dr. Sherman explains the recent data surrounding the right candidates for long-acting cabotegravir for HIV prevention.